Previous 10 | Next 10 |
2023-06-29 12:00:00 ET Summary Where do you put money that you need? I have some big upcoming checks to write. Here are ideas for protecting earmarked principal. Activision My Activision Blizzard, Inc. ( ATVI ) calls will be fantastic if the FTC l...
2023-06-29 05:08:31 ET Morgan Stanley is making some moves in its model for income-focused investors. It is adding two new positions with Rio Tinto ( NYSE: RIO ) and Smith & Nephew ( SNN ), swapping out Amgen ( AMGN ) and the iShares MSCI Hong Kong ETF ( EWH ). ...
2023-06-27 17:50:30 ET Summary The primary endpoint of MoonLake Immunotherapeutics' HiSCR75 was met with statistical significance in the phase 2 MIRA trial, when Hidradenitis suppurativa patients were treated with sonelokimab. The global Hidradenitis Suppurativa market is expected...
2023-06-26 11:37:57 ET Summary WisdomTree International High Dividend Fund holds over 500 high-yield stocks from developed countries. 63% of assets is in 5 countries and 40% is in 2 sectors. Valuation is unattractive relative to one of its main competitors. The fund has lo...
2023-06-21 10:56:39 ET Summary Novartis has struck a deal to acquire Chinook Therapeutics for $3.5 billion in cash, with Chinook shareholders set to gain $40 per share and a potential additional $300 million if regulatory hurdles are cleared. By buying Chinook, Novartis will be ab...
2023-06-20 06:58:24 ET Summary Ionis Pharmaceuticals' phase 2 study showed that patients treated with donidalorsen through week 17 achieved a 90% reduction in hereditary angioedema attack compared to placebo; the second dose brought a 97% reduction. Clinical trial results from the...
2023-06-19 10:15:00 ET Earlier this month, Novartis ' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to severe hidradenitis suppurativa (HS). What was the reason...
2023-06-18 04:24:59 ET Summary SomaLogic presents with a lack of fundamental, sentimental, and valuation factors to suggest a price change. I've revised my investment thesis to hold, due to the firm's Q1 results, revenue headwinds, and a market valuation of 0.8x book value. I ...
2023-06-17 16:00:00 ET Biologic drugs, among the most expensive medications that are often used in treating cancer and rare diseases, will propel European pharmaceutical companies to achieve more in sales than their US counterparts. By 2028, three of the top five pharma companies in ter...
2023-06-12 16:13:12 ET Summary Novartis announced the acquisition of Chinook Therapeutics for $3.5 billion, boosting its pipeline and expanding into the kidney disease market. The deal can be paid for with around three months' worth of Novartis' free cash generation, and the compa...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...